AlzeCure Pharma AB
https://www.alzecurepharma.se/sv/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AlzeCure Pharma AB
Eisai’s Alzheimer’s Pipeline Offers Combination Therapy Potential
Eisai is testing its anti-tau antibody in combination with the anti-amyloid therapy Leqembi, and earlier-stage programs targeting TrkA, EphA4 and TREM2 offer new approaches and combo potential.
AlzeCure Confident Of Bagging Partner For Pain Drug
The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440, its TRPV1 antagonist for neuropathic pain.
AlzeCure Hunts For Small Molecules In Its Alzheimer’s Quest
Emerging Company Profile: Swedish biotech AlzeCure is developing a portfolio of small-molecule drug candidates for diseases affecting the central nervous system, including Alzheimer’s disease and pain.
Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice